Testing if antivirals prevent long-term heart problems after COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests whether two antiviral medications, Paxlovid and Veklury (remdesivir), can reduce the risk of long-term heart and blood vessel problems after a COVID-19 infection. It is for adults recently hospitalized with COVID-19 who are not currently on oxygen therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You tested positive for COVID-19 within the last 5 days and are currently in the hospital
- You are breathing normally without needing extra oxygen
- You are not pregnant or breastfeeding
- You have not taken Paxlovid or Veklury in the last 14 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This study tests whether medicines that fight viruses (similar to those used for herpes or COVID) can reduce Long COVID symptoms like fatigue and brain fog. Researchers believe lingering viruses or viral reactivation may drive Long COVID, and this trial will see if antiviral drugs help.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
This trial tests a care program designed to help people who continue to have symptoms after recovering from COVID-19. It aims to prevent long-term health problems and improve well-being.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
Hear when a new SARS CoV-2 Post-Acute Sequelae trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.